Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pyxis Oncology (NASDAQ:PYXS) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other equities research analysts have also recently issued reports on PYXS. Royal Bank Of Canada dropped their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. Stifel Nicolaus lowered their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday, March 24th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $1.27 on Friday. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The business has a 50-day simple moving average of $1.48 and a two-hundred day simple moving average of $2.50. The firm has a market cap of $79.79 million, a price-to-earnings ratio of -0.98 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter, compared to analysts’ expectations of $0.13 million. As a group, research analysts predict that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Maia Wealth LLC purchased a new position in shares of Pyxis Oncology during the 4th quarter worth $25,000. Engineers Gate Manager LP bought a new stake in shares of Pyxis Oncology during the 4th quarter valued at $26,000. Fox Run Management L.L.C. purchased a new stake in shares of Pyxis Oncology in the 4th quarter worth $26,000. Avanza Fonder AB purchased a new stake in shares of Pyxis Oncology in the 4th quarter worth $31,000. Finally, XTX Topco Ltd bought a new position in Pyxis Oncology in the 2nd quarter worth $40,000. 39.07% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.